REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets genetic driver in High-Risk blood disorders
Disease control Recruiting nowThis study is testing whether a drug called enasidenib, sometimes combined with another drug called azacitidine, can help control high-risk myelodysplastic syndrome (MDS) in patients who have a specific genetic mutation called IDH2. The trial includes 63 patients who either haven…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New chemo combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new chemotherapy combination called CPX-351 in adults with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and under…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for tough blood cancers: Four-Drug attack trial opens
Disease control Recruiting nowThis trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC